Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rescigno

Showing results (641-650 of 1,117) with videos related to

Pageof 112
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Plos One|May 7, 2024
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern ItalyRaffaele Galiero, Giuseppe Loffredo, Vittorio Simeon, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Minerva Urology and Nephrology|June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 studyPasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Journal of Clinical Medicine|October 27, 2022
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA StudyRaffaele Galiero, Vittorio Simeon, Giuseppe Loffredo, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancer Cell|September 20, 2024
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancerBianca Calì, Martina Troiani, Silvia Bressan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Genomic correlates of clinical outcome in advanced prostate cancerWassim Abida, Joanna Cyrta, Glenn Heller, et al.
Pageof 112

Showing results (641-650 of 1,117) with videos related to

Sort By:
Pageof 112
European Journal of Cancer (Oxford, England : 1990)|September 23, 2025
<sup>177</sup>Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 studyPhilipp Mandel, Daniel Groener, Giulia Follacchio, et al.
Cancer Immunology, Immunotherapy : CII|February 3, 2026
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 studyMichele Maffezzoli, Alessio Signori, Alessandro Acunzo, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Plos One|May 7, 2024
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern ItalyRaffaele Galiero, Giuseppe Loffredo, Vittorio Simeon, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Minerva Urology and Nephrology|June 23, 2026
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 studyPasquale Rescigno, Tarek Taha, Maria J Fita, et al.
Journal of Clinical Medicine|October 27, 2022
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA StudyRaffaele Galiero, Vittorio Simeon, Giuseppe Loffredo, et al.
European Urology Oncology|November 29, 2024
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 StudyMatteo Santoni, Thomas Büttner, Pasquale Rescigno, et al.
Cancer Cell|September 20, 2024
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancerBianca Calì, Martina Troiani, Silvia Bressan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2019
Genomic correlates of clinical outcome in advanced prostate cancerWassim Abida, Joanna Cyrta, Glenn Heller, et al.
Pageof 112